CerviLenz

CerviLenz was a medical device company focused on improving maternal and fetal health outcomes by providing tools for the early detection of preterm birth risk. The company's primary product, the CerviLenz device, is a single-use clinical tool designed to measure cervical length during a routine speculum exam. By providing an objective measurement, the device helps clinicians identify pregnant women at high risk for premature labor, enabling timely interventions such as progesterone therapy. Headquartered in Chagrin Falls, Ohio, CerviLenz was backed by several venture capital firms before its acquisition by Clinical Innovations in 2016. The technology is currently part of the Laborie Medical Technologies portfolio.